Short Interest in Yarrow Bioscience (NASDAQ:YARW) Rises By 190.8%

Key Points

• Short interest surged 190.8% to 56,499 shares as of August 31, representing approximately 2.2% of Yarrow Bioscience’s outstanding stock and 1.2 days of average trading volume.
• Institutional ownership is substantial at 83.78%, with several firms—including BlackRock, Two Sigma Securities, and Boothbay Fund Management—initiating positions recently.
• Yarrow reported weak quarterly results, losing $3.51 per share versus the $0.18 consensus estimate and generating $0.10 million in revenue. Analysts’ consensus rating is Hold, with a $58 price target compared with a recent share price of $27.01.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 56,499 shares, an increase of 190.8% from the August 15th total of 19,427 shares. Based on an average trading volume of 46,917 shares, the short-interest ratio is currently 1.2 days. Approximately 2.2% of the company's stock are sold short.

Institutional Investors Weigh In On Yarrow Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of YARW. Two Sigma Securities LLC purchased a new position in Yarrow Bioscience during the 2nd quarter worth $26,000. BlackRock Inc. purchased a new stake in shares of Yarrow Bioscience in the 2nd quarter worth $29,000. GSA Capital Partners LLP purchased a new stake in shares of Yarrow Bioscience in the 2nd quarter worth $47,000. XTX Topco Ltd bought a new position in shares of Yarrow Bioscience during the 4th quarter worth $46,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Yarrow Bioscience during the 2nd quarter worth $176,000. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

Yarrow Bioscience Price Performance

NASDAQ YARW opened at $27.01 on Friday. Yarrow Bioscience has a twelve month low of $14.68 and a twelve month high of $46.95. The stock has a market capitalization of $72.12 million, a PE ratio of -1.84 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($3.33). Yarrow Bioscience had a negative return on equity of 84.40% and a negative net margin of 4,726.21%.The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.20 million.

Yarrow Bioscience Dividend Announcement

The company also recently declared a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were issued a dividend of $19.00 per share.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on YARW shares. BTIG Research assumed coverage on shares of Yarrow Bioscience in a research report on Monday, August 3rd. They set a "buy" rating and a $58.00 price objective on the stock. TD Cowen initiated coverage on shares of Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a "buy" rating for the company. Finally, Wall Street Zen upgraded shares of Yarrow Bioscience to a "hold" rating in a research note on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $58.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.